1	Frequency of antimicrobial-resistant bloodstream infections in Thailand, 2022
2	
3	Running Title: AMR BSI in Thailand, 2022
4	
5	Krittiya Tuamsuwan, Panida Chamawan, Phairam Boonyarit, Voranadda Srisuphan, Preeyarach
6	Klaytong, Chalida Rangsiwutisak, Prapass Wannapinij, Trithep Fongthong, John Stelling, Paul
7	Turner, Direk Limmathurotsakul.
8	
9	The Office of Permanent Secretary, Ministry of Public Health, Nonthaburi, 11000, Thailand
10	(K.T., P.C., P.B., V.S., T.F.)
11	Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol
12	University, Bangkok, Thailand (P.K., C.R., P.W., D.L.)
13	Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States (JS)
14	Cambodia-Oxford Medical Research Unit, Angkor Hospital for Children, Siem Reap, Cambodia
15	(PT)
16	Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of
17	Oxford, Oxford, United Kingdom (P.T., D.L.)
18	Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok,
19	Thailand (D.L.)
20	
21	Corresponding author: Prof. Direk Limmathurotsakul, Mahidol-Oxford Tropical Medicine
22	Research Unit, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok,
23	10400, Thailand. Tel: +66 2 203 6333, Fax: +66 2 354 9169, e-mail: direk@tropmedres.ac
24	
25	Word count: Abstract 200; Text 3,735; Tables 4; Figures 2
26	

- 27 Key words: Antimicrobial resistant, surveillance, bloodstream infection, proportion, incidence,
- 28 frequency
- 29

30 Declaration of interest: none

- 31
- 32 **ORCID**
- 33 Preeyarach Klaytong 0000-0002-9906-5159
- 34 Chalida Rangsiwutisak 0009-0007-9380-9085
- 35 Paul Turner 0000-0002-1013-7815
- 36 Direk Limmathurotsakul 0000-0001-7240-5320
- 37

38 Highlights

- The frequency of AMR BSI in 111 public hospitals in Thailand in 2022 was studied.
- The frequency of community-origin 3GCREC BSI was different by regions.
- The frequency of hospital-origin CRAB BSI varied greatly among hospitals.
- Underuse of BC was associated with the higher frequency of AMR BSI per tested
 patients.
- Our findings contributed to actions against AMR at local and national levels.
- 45

46 **Abstract**

47 **Objectives**

48 To evaluate the frequency of antimicrobial-resistant bloodstream infections (AMR BSI) in 49 Thailand

50

51 Methods

52 We analyzed data from 2022, generated by 111 public hospitals in health regions 1 to 12, using 53 the AutoMated tool for Antimicrobial resistance Surveillance System (AMASS) and submitted to

54 the Ministry of Public Health, Thailand. Multilevel Poisson regression models were used.

55

56 Results

57 The most common cause of community-origin AMR BSI was third-generation cephalosporin-58 resistant Escherichia coli (3GCREC, 65.6%; 5,101/7,773 patients) and of hospital-origin AMR 59 BSI was carbapenem-resistant Acinetobacter baumannii (CRAB, 51.2%, 4,968/9,747 patients). 60 The percentage of patients tested for BSI was negatively associated with the frequency of 61 community-origin 3GCREC BSI and hospital-origin CRAB BSI. Hospitals in health regions 4 62 (lower central) had the highest frequency of community-origin 3GCREC BSI per 100,000 tested 63 patients (adjusted incidence rate ratio, 2.06; 95% confidence interval: 1.52-2.97). Health regions 64 were not associated with the frequency of hospital-origin CRAB BSI, although between-hospital 65 variation was high even adjusting for hospital level and size.

66

67 **Conclusion**

The high between-hospital variation of hospital-origin CRAB BSI suggests the importance of hospital-specific factors. Our approach and findings highlight health regions and hospitals where actions against AMR infection, including antimicrobial stewardship and infection control, should be prioritized.

72

73 Introduction

74 Strengthening the knowledge and evidence base through surveillance and research is one of 75 the five key objectives outlined in the global action plan on antimicrobial resistance (AMR), led 76 by the World Health Organization (WHO) [1]. At the global level, the WHO Global Antimicrobial 77 Resistance and Use Surveillance System (GLASS) has provided a standard approach to the 78 collection, analysis and sharing of data [2]. The GLASS country profile dashboard presents 79 summaries of AMR data (including AMR proportions and AMR frequency) that each country 80 reported to the system [3]. In addition, many high-income countries (HICs), such as England, 81 have collated and made local AMR data available via a publicly accessible web tool [4]. Better 82 access, use and research on surveillance data have been one of the main elements to tackle 83 AMR [4-6].

84

85 In 2020, we developed the AutoMated tool for Antimicrobial resistance Surveillance System 86 (AMASS), an offline application that allow hospitals to automatically analyse and generate 87 standardized antimicrobial resistance (AMR) surveillance reports from their routine microbiology 88 and hospital data [7]. This tool was designed to overcome the limitations of inadequate human 89 resources to analyze AMR data and generate summary reports in low and middle-income 90 countries (LMICs). The automatically generated reports stratify infection origin into community-91 origin and hospital-origin based on the recommendations of WHO GLASS [2] and provide 92 additional reports on mortality (%) and total number of deaths following AMR and non-AMR 93 bloodstream infections (BSI). We initially tested the application in seven hospitals in seven 94 countries [7]. We recently reported the difference of frequency of hospital-origin AMR BSI 95 between tertiary-care hospitals (TCHs) and secondary-care hospitals (SCHs) using the AMASS 96 and a retrospective data in 49 public hospitals from 2012 to 2015 [8]. From December 2022 to 97 January 2023, on behalf of the Health Administration Division, Ministry of Public Health (MoPH)

98 Thailand, we trained 25 public hospitals in Thailand to utilize the AMASS, and reported the 99 benefit of local and timely AMR data review [9].

100

Following the success of the early implementation of the AMASS in 25 public hospitals [9], in 2023 the MoPH invited all 127 public referral hospitals in Thailand to utilize the AMASS using their data from 2022 and submit the summary data to the MoPH. This study aims to evaluate the frequency of community-origin and hospital-origin AMR BSI in Thailand.

105

106 Materials and Methods

107 Study setting

108 In 2022, Thailand had a population of 66.1 million, consisted of 77 provinces, and covered 109 513,120 km². The health systems in each province were integrated into 12 groups of provinces, 110 known as health regions, plus the capital Bangkok as health region 13 (Figure 1A), using the 111 concept of decentralization [10]. The Health Administration Division, Ministry of Public Health 112 (MoPH) supervised 127 public referral hospitals in health regions 1 to 12. These included 35 advanced-level referral hospital (i.e. level A, with a bed size of about 500-1,200), 55 standard-113 114 level referral hospital (i.e. level S, with a bed size of about 300-500) and 37 mid-level referral 115 hospital (i.e. level M1, with a bed size of about 180-300) [11]. All level A and S hospitals, and 116 most of level M1 hospitals were equipped with a microbiology laboratory capable of performing 117 bacterial culture using standard methodologies for bacterial identification and susceptibility 118 testing provided by the Department of Medical Sciences, MoPH.

119

120 Study tool and its implementation

From 16 December 2022 to 30 June 2023, on behalf of the Health Administration Division, MoPH, we invited and trained staff from 127 public referral hospitals in health regions 1 to 12 to utilize the AMASS with their own microbiology and hospital admission data files via four online

meetings, five face-to-face meetings and on-line support. Then, the MoPH invited all 127 public referral hospitals to utilize the AMASS in 2023 using their data from 2022. The additional two online meetings for 127 hospitals were conducted in January 2023, and the four face-to-face meetings were conducted in Chonburi (for hospitals in health regions 4, 5 and 6), Chiang Mai (for hospitals in health regions 1, 2 and 3), Surajthani (for hospitals in health regions 11 and 12) and Khon Kaen (for hospital in health regions 7, 8, 9 and 10) provinces in January and February 2023.

131

132 The content of the online meetings and face-to-face meetings were as previously described [9]. 133 In short, we taught the hospitals how to use the AMASS, complete the data dictionary files, and 134 verify and read the AMR reports automatically generated by the AMASS. The hospitals were 135 request to validate the reports using two methods: (a) checking data verification log files 136 generated the AMASS whether all information was imported accurately (e.g. total number of 137 specimens, total number of hospital admissions, number of missing values, total number of 138 isolates per organism in the raw microbiology data file, total number of antibiotics being tested, 139 and all pathogens and antimicrobial susceptibility testing results under evaluation), and (b) 140 comparing the summary data and reported generated by the AMASS with data generated from 141 manual calculations obtained from complete line listing of several organisms. The hospitals 142 were asked to re-export the data files (if needed), complete the data dictionary files, re-run the 143 AMASS and verify the reports until the reports were accurate. The 25 hospitals who were 144 initially trained in the first round [9] supported the other hospitals in their health regions.

145

Then, the hospitals who completed the utilization of the AMASS submitted the summary data generated by the AMASS to the MoPH. A new interactive Thailand AMR dashboard was launched in 2023 and is open-access (Figure 2) [12].

150 Study design

151 This is a retrospective study evaluating frequency of AMR BSI across public referral hospitals in 152 Thailand using the hospital-level AMR data submitted to the MoPH. For AMR infections, we 153 initially analyzed the following organisms: carbapenem-resistant Acinetobacter baumannii 154 (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), carbapenem-resistant 155 Escherichia coli (CREC), carbapenem-resistant Klebsiella pneumoniae (CRKP), third-156 generation cephalosporin-resistant E. coli (3GCREC) and K. pneumoniae (3GCRKP), and 157 methicillin-resistant Staphylococcus aureus (MRSA) which are in the WHO GLASS priority list of 158 AMR bacteria and are of locally importance. Only blood culture (BC) results were included in the 159 analysis of the AMASS and in this study. The AMASS de-duplicated the data by selecting only 160 the first admission of a patient with BSI caused by a given bacterial species per patient per 161 reporting period and per infection origin.

162

163 **Definitions**

164 Community-origin BSI was defined for patients with first positive blood specimens in the hospital 165 taken within the first two calendar days of admission with calendar day one equal to the day of 166 admission [13]. Patients with first positive blood specimens taken after the first two calendar 167 days were categorized as cases of hospital-origin BSI. The classification of community-origin 168 and hospital-origin BSI was performed within the AMASS and based on specimen collection 169 dates and hospital admission dates extracted from the microbiology and hospital data files of 170 each hospital. Blood specimens collected from patients who were not admitted at the study 171 hospitals were excluded from the analysis. These specimens were categorized as BSI of 172 unknown origin in the summary reported generated by the AMASS [7].

173

Patients who had the first BC taken within the first two calendar days of hospital admission were considered as having tested for community-origin BSI. Patients were considered at risk for

hospital-origin BSI after they stayed in the hospital for more than two calendar days. Patients
who had the first BC taken after the first two calendar days of hospital admission were
considered as having tested for hospital-origin BSI.

179

The proportion of AMR (%) was calculated as the percentage of patients with new AMR BSI over all patients with new BSIs for each pathogen during the reporting period. The frequency of AMR BSI for each pathogen was calculated as the total number of new patients with AMR BSI during the reporting period per 100,000 tested patients, per 100,000 admissions and per 100,000 patient-days at risk for hospital-origin BSI.

185

Mortality (%) following AMR BSI for each pathogen under evaluation was calculated as the percentage of patients with new AMR BSI who died in the hospital, using all-cause in-hospital mortality in the discharge summary regularly completed by the attending physicians and available in the admission data of the hospitals.

190

191 Statistical analysis

192 Medians, interquartile ranges (IQR) and ranges of continuous variables were estimated. IQRs 193 are presented in terms of 25th and 75th percentiles. For percentages, one digit after the decimal 194 points is shown when the total number of denominators is higher than 100. To evaluate BC 195 utilization, we calculated percentage of patients tested for BSI and rate of patients tested for BSI 196 per 1,000 bed-days. We did not calculate the total number of BC specimens per 1,000 bed-days 197 [14, 15], because, during the workshops, we observed that some hospitals recorded two BC 198 specimens as two separate records, while some hospitals recorded those as a single record in 199 their laboratory information systems (LIS). Therefore, we utilized the deduplicated number of 200 patients tested for BSI as the indicator of BC utilization. Kruskal Wallis test was used to 201 compare the median of continuous variables between groups.

202

We evaluated factors associated with the frequency of community-origin 3GCREC BSI and 203 204 hospital-origin CRAB BSI using univariable and multivariable Poisson random-effects regression 205 models. The community-origin 3GCREC BSI and hospital-origin CRAB BSI were selected as 206 they were the most common causes of community-origin and hospital-origin AMR BSI, 207 respectively. The random effect model accounts for the fact that the observed outcomes for 208 some hospitals can take on extreme values because of random variation. Factors evaluated 209 included health region, hospital level, hospital bed size, Gross Provincial Product (GPP), rate of 210 patients having BC taken per 1,000 patient-days, percentage of patients having BC taken within 211 the first two calendar days of hospital admission (for community-origin AMR BSI) and 212 percentage of patients having BC taken after first two calendar days of hospital admission (for 213 hospital-origin AMR BSI). Data of GPP of Thailand in 2021 was used as a proxy for the size of 214 the economy in each province [16]. We summarized results with incidence rate ratio (IRRs) and 215 95% confidence intervals (Cis).

216

217 To measure heterogeneity in the multilevel Poisson regression, we calculated the median rate 218 ratio (MRR) and variance partition coefficient (VPC) using the methods described by Austin et al 219 [17] (Appendix A). The MRR is the median relative change in the rate of the occurrence of the 220 event when comparing two hospitals (i.e. two clusters) with identical covariates from two 221 randomly selected different hospitals. The VPC denotes the proportion of the (unexplained) 222 variation in the outcome that is beyond that explained by the fixed effects of the covariates in 223 the models. In other words, the VPC denotes the proportion of the variation that is due to 224 between-hospital (i.e. between-cluster) variation [17]. We calculated the VPC using exact 225 calculations [17] and total number of tested patients for 111 covariate patterns of the 111 226 hospitals included in the study. We used STATA (version 14.2; College Station, Texas) for all 227 analyses.

228

229 Data availability

- 230 The hospital-level summary data used for the study are open-access and available at
- 231 https://figshare.com/s/6aee792c15290d7dea3c.
- 232
- 233 Ethics
- 234 Ethical permission for this study was obtained from the Institute for the Committee of the Faculty
- of Tropical Medicine, Mahidol University (TMEC 23-085). Individual patient consent was not
- sought as this was a retrospective study using summary data, and the Ethical and Scientific
- 237 Review Committees approved the process.

238

239

240 **Results**

241 Baseline characteristics

Of 127 public referral hospitals, 116 (91%) used the AMASS to analyze their microbiology and hospital admission data files, and submitted the summary AMR surveillance reports and data from 2022 to the MoPH. Four hospitals had no data of BC with 'no growth' results in the electronic data file, and one hospital exported and used inaccurate hospital admission data. These hospitals were removed from the analysis because the data of 'no growth' specimens and accurate data of hospital admissions were required for calculating the frequency of AMR BSI. Therefore, a total of 111 hospitals were included in the final analysis.

249

Of all public referral hospitals in Thailand, 100% of Level A hospitals (35/35), followed by 89% of Level S hospitals (49/55) and 73% of Level M1 hospitals (27/37) were included in this study. The data were available from 74 of 77 provinces (96%) in Thailand, all provinces except Mae

Hong Son, Nakorn Nayok and Bangkok.

254

From 1 January to 31 December 2022, there were 3,916,766 hospital admissions of 3,042,979 patients, totaling 23,675,466 patient-days, across 111 public referral hospitals included in the study. Hospital characteristics are presented in Table 1 and S1. A total of 618,187 patients had BC taken, resulting in 20.3% of patients having BC taken (618,187/3,024,360). Rate of patients having BC taken was 26.1 per 1,000 patient-days (618,187/23,541,908).

260

The median percentage of patients having BC taken within the first two calendar days of hospital admission was highest in Level A hospitals (18.8%), followed by that in Level S (16.5%) and Level M1 (15.0%) hospitals (p=0.11). The median percentage of patients having the first BC taken after the first two calendar days of hospital admission was also highest in Level A hospitals (4.2%), followed by that in Level S (3.3%) and Level M1 (2.6%) hospitals (p<0.001).

266

267 Total No. of cases and deaths following AMR BSI

There were 7,829 patients with community-origin AMR BSI caused by the pathogens under evaluation (Table 2). The most common cause of community-origin AMR BSI was 3GCREC, accounting 65.9% (5,157/7,829) of those patients. The total number of deaths following community-origin 3GCREC BSI was 1,048, representing 54.1% (1,048/1,936) of all deaths following community-origin AMR BSI caused by pathogens under evaluation.

273

There were 9,567 patients with hospital-origin AMR BSI caused by the pathogens under evaluation. The most common cause of hospital-AMR BSI was CRAB, accounting 51.3% (4,926/9,602) of those patients. The total number of deaths following hospital-origin CRAB BSI was 2,955, representing 58.7% (2,955/5,036) of all deaths following hospital-origin AMR BSI caused by pathogens under evaluation.

280 Factors associated with the frequency of community-origin 3GCREC BSI

281 The median observed frequency of community-origin 3GCREC BSI per 100,000 patients tested 282 for community-origin BSI was 961 in Level A hospitals, 1,008 in Level S hospitals and 911 in 283 Level M1 hospitals. In the multivariable regression model (Table 3), hospital level and bed size 284 were not associated with the frequency of community-origin 3GCREC BSI (p=0.50 and 0.14, 285 respectively). Hospital region was independently associated with the frequency (p<0.001). 286 Hospitals in health regions 4 and 12 were associated the highest and lowest frequency, 287 respectively, and the adjusted incidence rate ratio (aIRR) was about double (aIRR, 2.07; 95%) 288 confidence interval [CI] 1.53-2.80; Figure 1B). Rate of patients having BC taken per 1,000 289 patient-days was not included in the final model because of collinearity with the other variable 290 for BC utilization. Percentage of patients having BC taken within the first two calendar days of 291 hospital admission was negatively associated with the frequency of community-origin 3GCREC 292 BSI (aIRR 0.88, 95%CI 0.82-0.94, per 5 percentage point change, p<0.001).

293

There was between-hospital variation in the frequency of community-origin 3GCREC BSI in the final multivariable regression model (the estimated variance of the distribution of the random effects=0.066, p<0.001). The MRR was 1.28, representing the magnitude of between-hospital variation in the frequency of community-origin 3GCREC BSI. The median VPC was 0.71 (Figure S1 and S2), suggesting that, on average, 71% of the variation in the number of patients with community-origin 3GCREC BSI was due to differences between hospitals, while the remaining 29% was based on factors included in the final multivariable models.

301

302 Similar findings were also observed for the frequency of community-origin 3GCREC BSI per 303 100,000 admissions (Table S2), except that percentage of patients having BC taken within the 304 first two calendar days of hospital admission was positively associated with the frequency of

community-origin 3GCREC BSI per 100,000 admissions (aIRR 1.20, 95%CI 1.12-0.30, per 5
percentage point change, p<0.001).

307

308 Factors associated with the frequency of hospital-origin CRAB BSI

309 The median observed frequency of hospital-origin CRAB BSI per 100,000 patients tested for 310 hospital-origin BSI was 4,768 in Level A hospitals, 3,185 in Level S hospitals and 1,537 in Level 311 M1 hospitals. In the multivariable regression model (Table 4), hospital level and bed size were 312 independently associated with the frequency of hospital-origin CRAB BSI (p=0.010 and 0.001, 313 respectively). Hospital region was not strongly associated with the frequency of hospital-origin 314 CRAB BSI (p=0.096). The percentage of patients having BC taken after the first two calendar 315 days of hospital admission was negatively associated with the frequency of hospital-origin 316 CRAB BSI (aIRR 0.91, 95%CI 0.82-1.00, per 1 percentage point change, p=0.060).

317

There was between-hospital variation in the frequency of hospital-origin CRAB BSI in the final multivariable regression model (the estimated variance of the distribution of the random effects=0.184, p<0.001). The MRR was 1.51, representing the magnitude of between-hospital variation in the frequency of hospital-origin CRAB. The median VPC was 0.84 (Figure S3), suggesting that on average 84% of the variation in the number of patients with hospital-origin CRAB BSI was due to differences between hospitals. Figure S4 shows the differences in the frequency of hospital-origin CRAB BSI of each hospital within the same hospital level.

325

Similar findings were also observed for frequency of hospital-origin CRAB BSI per 100,000 admissions and per 100,000 patient-days at risk, except that percentage of patients having BC taken after the first two calendar days of hospital admission was positively associated with the frequency of hospital-origin CRAB BSI per 100,000 admissions (aIRR 1.15, 95%CI: 1.04-1.28,

p=0.009, Table S3) and per 100,000 patient-days at risk of hospital-origin BSI (aIRR 1.09,
95%CI 0.99-1.20, p=0.092, respectively, Table S4).

- 332
- 333

334 Discussion

This study demonstrates the regional differences in frequency of community-origin 3GCREC BSI in Thailand in 2022 after adjustment for the difference in hospital level, hospital bed size and rate of patients having BC taken. Our study highlights the high variation of the frequency of hospital-origin CRAB BSI between hospitals, suggesting that unadjusted factors at the hospital level (e.g. differences in case-mix, and infection prevention control (IPC) and antimicrobial stewardship (AMS) activities) are important.

341

342 Some health regions (e.g. 4, 5 and 7; Figure 1B) had relatively higher frequency of community-343 origin 3GCREC BSI than the others. Lack of association between hospital level and the 344 frequency of community-origin 3GCREC BSI is consistent with the previous finding [8]. Our 345 study did not observe an association between the local economy (as measured by GPP) and 346 the frequency of community-origin 3GCREC BSI. Previous studies reported that regions, sex, 347 age and underlying diseases are associated with the incidence rate of AMR E. coli BSI [18, 19]. 348 Further studies are needed to evaluate whether these factors (using patient-level data) and 349 other factors (e.g. antibiotic consumption at the provincial-level or regional-level) are associated 350 with the frequency of community-origin 3GCREC BSI. Those insights would be crucial for 351 formulating targeted interventions against community-acquired AMR infections in the country.

352

Association between hospital level and bed size and the frequency of hospital-origin CRAB BSI is consistent with the previous findings [8, 20]. This is likely because large referral hospitals tend to have a higher proportion of patients with severe conditions, or requiring complex surgery,

356 prolonged intubation or urinary catheters, and a higher proportion of intensive care beds. 357 Further studies are needed to evaluate and adjust for these factors using patient-level data. The 358 substantial between-hospital variation for hospital-origin CRAB BSI may also be due to the 359 differences in effectiveness of IPC and AMS activities implemented in each hospital. Due to the 360 inability to adjust for differences in case-mix, we cannot conclusively determine whether hospitals with the highest frequency of hospital-origin CRAB BSI had less-effective IPC or AMS 361 362 activities. However, the MoPH is promptly prioritizing these hospitals for immediate actions, 363 including re-evaluation and reinforcement of IPC and AMS activities.

364

365 In line with previous studies [21, 22], our study shows that the under-utilization of BC could lead 366 to higher observed frequency of AMR BSI per 100,000 tested patients and the lower observed 367 frequency of AMR BSI per 100,000 admissions and per 100,000 patient-days. Possibly, 368 hospitals which under-utilize BC tend to perform BC sampling primarily among patients with 369 very severe infections or failure of empirical treatment. This would lead to a selection bias for 370 culture positivity for AMR pathogens (resulting in a higher frequency of AMR BSI per 100,000 371 tested patients being observed) and to misdiagnoses of AMR BSI in patients without BC taken 372 (resulting in a lower frequency per 100,000 admissions and per 100,000 patient-days being 373 observed) [21].

374

Our study has multiple strengths. First, the number of hospitals included in the analysis was large. We also included a wide range of hospital levels and size. Second, we calculated and adjusted for BC utilization in the multivariable models. Third, we systematically estimated the magnitude of between-cluster variation [17, 23].

379

However, our study also has several limitations. First, we utilized summary data. Individual-level
 data such as sex, age and underlying diseases were not available for analysis. Using individual-

382 level data and adjusting for patient-specific factors could reduce the VPC and MRR (i.e. 383 between-cluster variation) [23]. Second, the origin of infection was only a proxy for community-384 acquired and hospital-acquired infection [24], and data of inter-hospital patient transfers were 385 not available in our study. A proportion of patients with community-origin BSI, therefore, could 386 be caused by nosocomial infections acquired at transferring hospitals. Third, mortality reported 387 in this study was all-cause in-hospital mortality, and could be much lower than the true all-cause 388 mortality because a preference to die at home is high in some regions in Thailand [25]. Fourth, 389 the difference in the percentage of patients having BC taken could be due to the differences in 390 case-mix. Further studies could additionally utilize antimicrobial prescription data to determine 391 proportion of patients having a BC taken within ±1 calendar day of the day when a parenteral 392 antibiotic was started at the study hospital and continued for at least four consecutive days [21, 393 22]. This could improve our understanding of differences in diagnostic use practice between 394 hospitals and reinforce diagnostic stewardship activities in hospitals that underutilize BC among 395 sepsis patients.

396

397

398 **Conclusions**

399 Our findings highlight health regions where actions against community-acquired AMR infection, 400 including reduction of antibiotic overuse in the community, should be considered. Our findings 401 also highlight hospitals where actions against hospital-acquired AMR infection, including 402 antimicrobial stewardship, infection control and diagnostic stewardship, should be prioritized.

403 Acknowledgements

- 404 We gratefully acknowledge the laboratory team, IT team, antimicrobial stewardship team and
- 405 infection control team of all public referral hospitals in Thailand for their participation in the
- 406 activities of the Ministries of Public Health (MoPH), including utilization of the AMASS and
- 407 submission of summary data to the MoPH.
- 408

409 **Funding**

- 410 The study is supported by Ministry of Public Health Thailand and Wellcome Trust of Great
- 411 Britain (224681/Z/21/Z). For the purpose of Open Access, the author has applied a CC BY
- 412 public copyright licence to any Author Accepted Manuscript version arising from this
- 413 submission.
- 414
- 415 **Transparency declarations**
- 416 We declare that no competing interests exist.
- 417

418 **References**

- 419 1. WHO. Global Action Plan on Antimicrobial Resistance2015. Available from:
- 420 https://www.who.int/publications/i/item/9789241509763.
- 421 2. WHO. WHO report on surveillance of antibiotic consumption. 2016-2018 early
- 422 implementation. 2019. Available from: <u>https://www.who.int/publications/i/item/who-report-on-</u>
- 423 <u>surveillance-of-antibiotic-consumption</u>.
- 424 3. WHO. Global antimicrobial resistance and use surveillance systems | Country Profiles
- 425 [Available from: <u>https://www.who.int/data/gho/data/themes/topics/global-antimicrobial-</u>
- 426 resistance-surveillance-system-glass/glass-country-profiles.
- 427 4. Johnson AP, Muller-Pebody B, Budd E, Ashiru-Oredope D, Ladenheim D, Hain D, et al.

428 Improving feedback of surveillance data on antimicrobial consumption, resistance and

429 stewardship in England: putting the data at your Fingertips. J Antimicrob Chemother.

430 2017;72(4):953-6.

431 5. Ashiru-Oredope D, Cunningham N, Casale E, Muller-Pebody B, Hope R, Brown CS, et

432 al. Reporting England's progress towards the ambitions in the UK action plan for antimicrobial

resistance: the English surveillance programme for antimicrobial utilisation and resistance

434 (ESPAUR). J Antimicrob Chemother. 2023;78(10):2387-91.

Walter J, Haller S, Blank HP, Eckmanns T, Abu Sin M, Hermes J. Incidence of invasive
meticillin-resistant Staphylococcus aureus infections in Germany, 2010 to 2014. Euro Surveill.

437 2015;20(46).

438 7. Lim C, Miliya T, Chansamouth V, Aung MT, Karkey A, Teparrukkul P, et al. Automating

the Generation of Antimicrobial Resistance Surveillance Reports: Proof-of-Concept Study

440 Involving Seven Hospitals in Seven Countries. J Med Internet Res. 2020;22(10):e19762.

441 8. Lim C, Hantrakun V, Klaytong P, Rangsiwutisak C, Tangwangvivat R, Phiancharoen C,

442 et al. Frequency and mortality rate following antimicrobial-resistant bloodstream infections in

- tertiary-care hospitals compared with secondary-care hospitals. PLoS One.
- 444 2024;19(5):e0303132.
- 9. Srisuphan V, Klaytong P, Rangsiwutisak C, Tuamsuwan K, Boonyarit P,
- Limmathurotsakul D. Local and timely antimicrobial resistance data for local and national
- 447 actions: the early implementation of an automated tool for data analysis at local hospital level in
- 448 Thailand. JAC Antimicrob Resist. 2023;5(4):dlad088.
- 10. Veerasarn K, Yuthagovit S, Chailorrat A. Prevalence of Brain Tumor in Thailand from
- 450 2005 to 2014: Data from the National Health Security Office. J Med Assoc Thai. 2016;99 Suppl
- 451 **3:S62-73**.
- 452 11. Ministry of Public Health, Thailand. List of Healthcare Facilities under Health
- 453 Administration Division, Ministry of Public Health, Thailand 2023. 2023. Available from:
- 454 <u>http://dmsic.moph.go.th/index/detail/9188</u>.
- 455 12. Ministry of Public Health, Thailand. AMR Surveillance and Monitoring MoPH Dashboard
- 456 2023. Available from:
- 457 <u>https://app.powerbi.com/view?r=eyJrljoiZGY0ZTcxNjMtYmNIZi000DAyLWEzYjctYzBhOGRIM2</u>
- 458 <u>ZIN2YxliwidCl6ljM1YjAwOTJjLTM1MDYtNDliYS1iMWFjLTU0NmQwOTI1NzEyZClsImMiOjEwf</u>
- 459 <u>Q%3D%3D</u>.
- 460 13. WHO. GLASS manual for antimicrobial resistance surveillance in common bacteria
- 461 causing human infection. 2023. Available from:
- 462 <u>https://iris.who.int/bitstream/handle/10665/372741/9789240076600-eng.pdf</u>
- 463 14. Sinto R, Lie KC, Setiati S, Suwarto S, Nelwan EJ, Djumaryo DH, et al. Blood culture
- 464 utilization and epidemiology of antimicrobial-resistant bloodstream infections before and during
- the COVID-19 pandemic in the Indonesian national referral hospital. Antimicrob Resist Infect
- 466 Control. 2022;11(1):73.

467 15. Teerawattanasook N, Tauran PM, Teparrukkul P, Wuthiekanun V, Dance DAB, Arif M, et

- 468 al. Capacity and Utilization of Blood Culture in Two Referral Hospitals in Indonesia and
- 469 Thailand. Am J Trop Med Hyg. 2017;97(4):1257-61.
- 470 16. National Statistical Office of Thailand. Statistical Yearbook Thailand 2023, 2023.
- 471 Available from: <u>https://www.nso.go.th/public/e-book/Statistical-Yearbook/SYB-2023</u>.

472 17. Austin PC, Stryhn H, Leckie G, Merlo J. Measures of clustering and heterogeneity in

473 multilevel Poisson regression analyses of rates/count data. Stat Med. 2018;37(4):572-89.

18. MacKinnon MC, McEwen SA, Pearl DL, Lyytikainen O, Jacobsson G, Collignon P, et al.

475 Increasing incidence and antimicrobial resistance in *Escherichia coli* bloodstream infections: a

476 multinational population-based cohort study. Antimicrob Resist Infect Control. 2021;10(1):131.

19. Laupland KB, Gregson DB, Church DL, Ross T, Pitout JD. Incidence, risk factors and

478 outcomes of *Escherichia coli* bloodstream infections in a large Canadian region. Clin Microbiol

479 Infect. 2008;14(11):1041-7.

480 20. Anugulruengkitt S, Charoenpong L, Kulthanmanusorn A, Thienthong V, Usayaporn S,

481 Kaewkhankhaeng W, et al. Point prevalence survey of antibiotic use among hospitalized

482 patients across 41 hospitals in Thailand. JAC Antimicrob Resist. 2023;5(1):dlac140.

483 21. Lim C, Hantrakun V, Teerawattanasook N, Srisamang P, Teparrukkul P, Sumpradit N, et

al. Impact of low blood culture usage on rates of antimicrobial resistance. J Infect.

485 2021;82(3):355-62.

Sinto R, Lie KC, Setiati S, Suwarto S, Nelwan EJ, Karyanti MR, et al. Diagnostic and
antibiotic use practices among COVID-19 and non-COVID-19 patients in the Indonesian
National Referral Hospital. PLoS One. 2024;19(3):e0297405.

489 23. Austin PC, Wagner P, Merlo J. The median hazard ratio: a useful measure of variance
490 and general contextual effects in multilevel survival analysis. Stat Med. 2017;36(6):928-38.

- 491 24. WHO. Global antimicrobial resistance surveillance system (GLASS) report: Early
- 492 implementation 2017-2018. 2019. Available from:
- 493 https://apps.who.int/iris/bitstream/handle/10665/279656/9789241515061-eng.pdf?ua=1.
- 494 25. Hongsuwan M, Srisamang P, Kanoksil M, Luangasanatip N, Jatapai A, Day NP, et al.
- 495 Increasing incidence of hospital-acquired and healthcare-associated bacteremia in northeast
- 496 Thailand: a multicenter surveillance study. PLoS One. 2014;9(10):e109324.

498 Table 1. Characteristics of 111 public referral hospitals in Thailand, 2022

Characteristics	Hospitals (N=111)
Total No. of bed size	54,564
Total No. of admissions	3,916,766
Total patient-days	23,675,466
Total No. of patients (de-duplicated)	3,042,979
Total No. of patients having BC taken (de-duplicated)*	618,187
Hospital characteristics	
Bed count, median (IQR)	421 (300-650)
No. of admissions, median (IQR)	27,847 (20,195-47,645)
Patient-days, median (IQR)	174,638 (115,129-287,015)
No. of patients, median (IQR)	22,399 (15,708-36,161)
No. of patients having BC taken, median (IQR) *	4,671 (2,768-7,222)
Percentage of patients having BC taken, median (IQR) **	20.0% (16.1-22.9%)
No. of patients having BC taken within the first two	3,880 (2,405-6,336)
calendar days of hospital admission, median (IQR) ***	
Percentage of patients having BC taken within the first	17.3% (13.1-20.2%)
two calendar days of hospital admission, median (IQR)	

No. of patients having the first BC taken after the first	815 (429-1,377)
two calendar days of hospital admission, median (IQR)	

Percentage of patients having the first BC taken after	3.4% (2.6-4.0%)
the first two calendar days of hospital admission,	
median (IQR) ***	
Rate of patients having BC taken per 1,000 patient-days,	26.4 (21.2-32.5)
median (IQR)	
Hospital level**	
Level A	35 (31.5%)
Level S	49 (24.3%)
Level M1	27 (44.1%)
Health regions	
1	10 (9.0%)
2	8 (7.2%)
3	5 (4.5%)
4	10 (9.0%)
5	15 (13.5%)
6	12 (10.8%)
7	6 (5.4%)
8	11 (9.9%)
9	7 (6.3%)
10	40 (40 00()
11	12 (10.8%)
12	9 (8.1%)

499

BC=blood culture. *For total No. of patients having BC taken, the AMASS deduplicated the data by
 selecting only the first BC per patient per surveillance period. **Hospital level is defined by the MoPH
 Thailand. Level A is Advanced-level referral hospital, Level S is Standard-level referral hospital, and Level
 M1 is Mid-level referral hospital. ***Some patients had more than one admission, of which one had the

504 first BC taken within the first two calendar days of hospital admission, and one had the first BC taken after 505 the first two calendar days of admission.

506

508 Table 2. Total No. of cases and deaths following AMR BSI in 111 public referral hospitals

509 **in Thailand, 2022**

AMR pathogens*	Total No. of patients	Total No. of in-hospital deaths	In-hospital mortality (%)
Community-origin BSI			
CRAB	664	343	51.7%
CRPA	300	67	22.3%
3GCREC	5,157	1,048	20.3%
3GCREC excluding CREC	4,758	953	20.0%
CREC	399	95	23.8%
3GCRKP	1,338	380	28.4%
3GCRKP excluding CRKP	860	222	25.8%
CRKP	478	158	33.1%
MRSA	370	98	26.5%
Total	7,829	1,936	24.7%
Hospital-origin BSI			
CRAB	4,926	2,955	60.0%
CRPA	484	241	49.8%
3GCREC	1,351	509	37.7%
3GCREC excluding CREC	1,072	381	35.5%
CREC	279	128	45.9%
3GCRKP	2,656	1,262	47.5%
3GCRKP excluding CRKP	1,078	428	39.7%
CRKP	1,578	834	52.9%
MRSA	185	69	37.3%
Total	9,602	5,036	52.4%

510

511 BSI=bloodstream infection * Included carbapenem-resistant Acinetobacter baumannii (CRAB),

512 carbapenem-resistant *Pseudomonas aeruginosa* (CRPA), third-generation cephalosporin-resistant

513 Escherichia coli (3GCREC) and Klebsiella pneumoniae (3GCRKP), carbapenem-resistant E. coli (CREC)

and K. pneumoniae (CRKP), and methicillin-resistant Staphylococcus aureus (MRSA).

516 **Table 3. Factors associated with the frequency of community-origin 3GCREC BSI per**

Ρ **Crude incidence** Ρ Adjusted Factors rate ratio (95% value incidence rate value CI) ratio (95% CI) 0.26 0.50 А 1.0 1.0 S 0.98 (0.82-1.17) 1.07 (0.84-1.36) M1 0.84 (0.68-1.05) 0.98 (0.71-1.33) Health regions 1.33 (1.14-1.55) < 0.001 1.38 (1.03-1.85) < 0.001 1 2 1.77 (1.52-2.07) 1.90 (1.40-2.56) 3 1.81 (1.53-2.15) 1.90 (1.35-2.67) 4 1.94 (1.67-2.25) 2.07 (1.53-2.80) 5 2.04 (1.78-2.35) 2.01 (1.52-2.65) 6 1.94 (1.68-2.23) 1.92 (1.37-2.68) 7 2.28 (1.97-2.62) 2.03 (1.47-2.80) 8 1.71 (1.48-1.97) 1.67 (1.26-2.22) 9 1.20 (1.04-1.40) 1.27 (0.92-1.75) 10 1.23 (1.04-1.44) 1.24 (0.89-1.73) 11 1.40 (1.20-1.62) 1.46 (1.10-1.94) 12 1.0 1.0 0.24 Hospital bed size (per 100 bed change)* 1.02 (0.99-1.05) 1.04 (0.99-1.09) 0.14 Gross provincial product* 1.08 (1.01-1.16) 0.034 0.99 (0.91-1.08) 0.83 Rate of patients having BC taken per 1,000 < 0.001 0.83 (0.77-0.90) patient-days* Percentage of patients having BC taken 0.83 (0.77-0.90) 0.88 (0.82-0.94) < 0.001 < 0.001 within the first two calendar days of hospital admission (per 5 percentage point change)*

517 **100,000 patients tested for community-origin BSI**

518

^{*} The rate ratios for the four continuous variables denote the relative change in the frequency of

community-origin 3GCREC BSI per 100,000 patients with the first BC taken within the first 2 calendar
 days of hospital admissions (i.e. patients tested for community-origin BSI). All four continuous variables
 were standardized by centering at the mean values and divided by the standard deviation, except that
 hospital bed size was divided by 100 and the percentage of patients tested for community-origin BSI by 5.
 The multivariable model consists of 5,157patients with community-origin 3GCREC BSI from 522,919
 patients tested for community-origin BSI from 111 hospitals.

526

527

529 Table 4. Factors associated with the frequency of hospital-origin CRAB BSI per 100,000

530 patients tested for hospital-origin BSI

Factors	Crude incidence rate ratio (95% CI)	P value	Adjusted incidence rate ratio (95% CI)	P value
Hospital levels				
A	1.0	<0.001	1.0	0.010
S	0.63 (0.49-0.79)		0.90 (0.62-1.32)	
M1	0.30 (0.22-0.41)		0.56 (0.34-0.93)	
Health regions				
1		0.40	1.33 (0.79-2.23)	0.096
2	1.58 (0.86-2.92)		2.11 (1.23-3.60)	
3	1.99 (1.00-3.97)		2.40 (1.31-4.38)	
4	1.49 (0.83-2.67)		1.99 (1.16-3.42)	
5	1.38 (0.81-2.36)		1.69 (1.03-2.78)	
6	1.83 (1.05-3.17)		1.93 (1.07-3.51)	
7	2.15 (1.10-4.17)		2.38 (1.35-4.20)	
8	1.26 (0.71-2.25)		1.57 (0.95-2.60)	
9	1.06 (0.56-2.03)			
10	1.11 (0.57-2.15)		1.18 (0.67-2.08)	
11	1.49 (0.85-2.61)		1.78 (1.07-2.98)	
12	1.54 (0.86-2.79)		1.76 (1.05-2.96)	
Hospital bed size (per 100 bed change)*	1.16 (1.11-1.21)	<0.001	1.15 (1.06-1.24)	0.001
Gross provincial product*	1.10 (0.98-1.23)	0.12	1.03 (0.90-1.17)	0.62
Rate of patients having BC taken per 1,000 patient-days*	0.99 (0.86-1.12)	0.83		-
Percentage of patients having BC taken after the first two calendar days of hospital admission (per 1 percentage point change)*	1.16 (1.05-1.27)	0.002	0.91 (0.82-1.00)	0.060

531

* The rate ratios for the four continuous variables denote the relative change in the frequency of hospitalorigin CRAB BSI per 100,000 patients with the first BC taken after the first 2 calendar days of hospital
admissions (i.e. patients tested for hospital-origin BSI). All four continuous variables were standardized by
centering at the mean values and divided by the standard deviation, except that hospital bed size was
divided by 100 and the percentage of patients tested for hospital-origin BSI by 1. The multivariable model
consists of 4,926 patients with hospital-origin CRAB BSI from 115,516 patients tested for hospital-origin

538 BSI from 111 hospitals.

540 Figure legends

541

542 Figure 1. Health regions in Thailand (1A) and expected frequency of community-origin

543 **3GCREC BSI (1B) by health regions**

- 544 Footnote of figure 1. For each health region, the expected frequency was estimated based on
- the total number of expected cases per the total number of patients tested for BSI in the
- 546 provinces. The number of expected cases was calculated using the fixed effects of the
- 547 covariates in the final model and assuming that all hospitals had the percentage of patients
- 548 having BC taken within the first 2 days of hospital admission at the mean value (16.9%).

549

550

551 **Figure 2. New interactive Thailand AMR dashboard** [12]

- 552 Footnote of figure 2. Thai words were translated to English and highlighted in green color. The
- 553 picture was captured from the website [12] on 30 June 2023.



